Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Putative catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. Additionally we are shipping Exosome Component 10 Antibodies (41) and many more products for this protein.
Showing 6 out of 9 products:
Rrp6: Integrated roles in nuclear RNA metabolism and transcription termination
EXOSC10 can be modified by SUMOylation and identifies a physiological stress where this regulation is prevalent both in vitro and in vivo.
Results show that DGCR8 (show DGCR8 Proteins) forms an alternative complex with the RRP6-containing form of the exosome, acts as an adaptor to recruit the exosome to target structured RNAs, and the DGCR8 (show DGCR8 Proteins)/hRRP6 complex controls the stability of human telomerase RNA.
Microprocessor orchestrates the recruitment of termination factors Setx (show SETX Proteins) and Xrn2 (show XRN2 Proteins), and the 3'-5' exoribonuclease, Rrp6, to initiate RNAPII pausing and premature termination at the HIV-1 promoter through cleavage of the stem-loop RNA, TAR (show RBM8A Proteins).
Systemic sclerosis patients with anti-PM-Scl antibody are younger and significantly more often have limited cutaneous involvement, skeletal muscle disease, pulmonary fibrosis and calcinosis.
Saccharomyces cerevisiae Rrp6, and determined the X-ray structure of a human construct containing the exoribonuclease and HRDC domains that retains catalytic activity
cloning of a more complete cDNA for PM/Scl-75 (show EXOSC9 Proteins) encoded 84 additional amino acids at its N terminus and only this longer polypeptide is able to associate with the exosome complex.
Although not required for exosome stability, PM/Scl-100 and PM/Scl-75 (show EXOSC9 Proteins) are involved in mRNA degradation.
Anti-PM/Scl antibodies are common in distinct SSc (show CYP11A1 Proteins) subsets and are associated with several clinical symptoms
PM-Scl-75 (show EXOSC9 Proteins) is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome.
Putative catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. EXOSC10 has 3'-5' exonuclease activity (By similarity). EXOSC10 is required for nucleolar localization of C1D and probably mediates the association of SKIV2L2, C1D and MPP6 wth the RNA exosome involved in the maturation of 5.8S rRNA (By similarity).
exosome component 10
, Exosome component 10
, P100 polymyositis-scleroderma overlap syndrome-associated autoantigen
, autoantigen PM-SCL
, autoantigen PM/Scl 2
, polymyositis/scleroderma autoantigen 100 kDa
, polymyositis/scleroderma autoantigen 2 (100kD)
, polymyositis/scleroderma autoantigen 2, 100kDa
, autoantigen PM/Scl 2 homolog
, polymyositis/scleroderma autoantigen 2 homolog